- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05158959
Association Between Renal Reserve Function and Progression of Renal Function to Predict CKD Risk in Thai Elderly
December 2, 2021 updated by: Kearkiat Praditpornsilpa, Chulalongkorn University
Study of the Association Between Renal Reserve Function and Progression of Renal Function to Predict Chronic Kidney Disease Risk in Thai Elderly
This study investigates renal functional reserve in elderly.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The prevalence of CKD in elder is high as age has been a variable in eGFR equation.
eGFR by calculation always declines in parallel with age.
The assumption that a persistent over 3 months of eGFR less than 60 mL/min/1.73m2
define CKD with risk of progression and need refer to nephrologist may not necessary true in aging population.
We study renal functional reserve in elderly population who risk of CKD progression and ESRD is the highest prevalence in human life cycle and explore whether renal functional reserve can be used as ad additional marker of CKD progression in elderly.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangkok, Thailand, 10330
- Recruiting
- Kearkiat Praditpornsilpa
-
Contact:
- Kearkiat Praditpornsilpa, MD
- Phone Number: 6602564251
- Email: kearkiat@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Elders age more than 60 years who are non-frail and has no limited life expectancy
Description
Inclusion Criteria:
- Patient age > 60 years at screening
- Patient willing to participate in the study and can provide inform consent
- Patient have residual kidney function ≤ 90 ml/min/1.73m2 by CKD-EPI equation
Exclusion Criteria:
- Patient active smoking
- Patient have Charlson comorbidity index > .....
- Patient active cancer
- Patient contraindications for blood collection
- Patients with a history of hypersensitivity to cimetidine or amino acid IV solution
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of renal functional reserve per 12 months (mL/min)
Time Frame: 12 months
|
Renal functional reserve defined as the difference between baseline creatinine clearance and creatinine clearance achieved under stimulation with amino acid infusion.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 24, 2019
Primary Completion (Anticipated)
June 30, 2022
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
December 2, 2021
First Submitted That Met QC Criteria
December 2, 2021
First Posted (Actual)
December 15, 2021
Study Record Updates
Last Update Posted (Actual)
December 15, 2021
Last Update Submitted That Met QC Criteria
December 2, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB NO.527/62
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Function Abnormal
-
Peking UniversityCompletedHypertension | Hypertension With Abnormal Renal FunctionChina
-
SanofiCompleted
-
Geisinger ClinicCompleted
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Principia Biopharma, a Sanofi CompanyCompletedHealthy Volunteers | Hepatic Function AbnormalUnited States
-
SanofiCompletedHepatic Function AbnormalUnited States, Germany
-
SanofiTerminatedHepatic Function AbnormalGermany, South Korea
-
SanofiCompletedHepatic Function AbnormalBulgaria, France
-
Northern Jiangsu People's HospitalNot yet recruitingPortal Hypertension | Cirrhosis, Liver | Splenectomy; Status | Renal Function Abnormal
-
Shanghai 10th People's HospitalCompletedChronic Kidney Disease | Hyperuricemia | Abnormal Renal FunctionChina